Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spike Glycoprotein, Coronavirus | 12 | 2025 | 215 | 3.760 |
Why?
|
| Viral Vaccines | 5 | 2021 | 324 | 1.780 |
Why?
|
| Recombinant Proteins | 12 | 2023 | 1319 | 1.760 |
Why?
|
| Lyme Disease | 5 | 2025 | 34 | 1.460 |
Why?
|
| Borrelia burgdorferi | 4 | 2025 | 18 | 1.310 |
Why?
|
| Vaccines, Synthetic | 4 | 2021 | 325 | 1.180 |
Why?
|
| Betacoronavirus | 2 | 2020 | 275 | 1.010 |
Why?
|
| Protein Domains | 8 | 2025 | 252 | 1.010 |
Why?
|
| Saccharomycetales | 5 | 2021 | 36 | 0.960 |
Why?
|
| Coronavirus Infections | 3 | 2021 | 339 | 0.930 |
Why?
|
| Ixodes | 2 | 2022 | 20 | 0.910 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2025 | 688 | 0.900 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 351 | 0.900 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2025 | 29 | 0.890 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 1 | 2025 | 22 | 0.880 |
Why?
|
| Pandemics | 3 | 2021 | 1118 | 0.860 |
Why?
|
| Vaccines, Subunit | 2 | 2024 | 75 | 0.840 |
Why?
|
| Protozoan Proteins | 2 | 2022 | 128 | 0.800 |
Why?
|
| Phlebotomus | 2 | 2020 | 14 | 0.780 |
Why?
|
| Leishmaniasis Vaccines | 2 | 2020 | 20 | 0.780 |
Why?
|
| Gene Expression | 4 | 2021 | 1481 | 0.740 |
Why?
|
| Trypanosoma cruzi | 2 | 2022 | 256 | 0.700 |
Why?
|
| Pichia | 2 | 2017 | 56 | 0.610 |
Why?
|
| Viral Envelope Proteins | 1 | 2020 | 155 | 0.590 |
Why?
|
| Chagas Disease | 2 | 2022 | 320 | 0.580 |
Why?
|
| Chromatography, Ion Exchange | 4 | 2014 | 37 | 0.560 |
Why?
|
| Saccharomyces cerevisiae | 6 | 2023 | 399 | 0.550 |
Why?
|
| Lyme Disease Vaccines | 4 | 2025 | 11 | 0.500 |
Why?
|
| Mice, Inbred BALB C | 6 | 2024 | 978 | 0.490 |
Why?
|
| Animals | 20 | 2025 | 33912 | 0.400 |
Why?
|
| Antibodies, Viral | 6 | 2024 | 1176 | 0.350 |
Why?
|
| Salivary Proteins and Peptides | 2 | 2020 | 18 | 0.320 |
Why?
|
| Alum Compounds | 3 | 2022 | 41 | 0.320 |
Why?
|
| Insect Proteins | 2 | 2020 | 95 | 0.310 |
Why?
|
| Cloning, Molecular | 3 | 2021 | 780 | 0.310 |
Why?
|
| Mice | 11 | 2025 | 18301 | 0.300 |
Why?
|
| Protozoan Vaccines | 2 | 2022 | 101 | 0.300 |
Why?
|
| Antibodies, Neutralizing | 6 | 2024 | 525 | 0.300 |
Why?
|
| Severe Acute Respiratory Syndrome | 2 | 2020 | 39 | 0.290 |
Why?
|
| Adjuvants, Immunologic | 3 | 2024 | 393 | 0.280 |
Why?
|
| Complement Factor H | 3 | 2025 | 24 | 0.260 |
Why?
|
| RNA | 1 | 2010 | 517 | 0.260 |
Why?
|
| Bacterial Proteins | 2 | 2025 | 953 | 0.250 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2025 | 437 | 0.240 |
Why?
|
| DNA | 1 | 2010 | 1399 | 0.220 |
Why?
|
| Cricetulus | 1 | 2025 | 90 | 0.220 |
Why?
|
| CHO Cells | 1 | 2025 | 152 | 0.220 |
Why?
|
| Epitopes | 2 | 2022 | 324 | 0.210 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2024 | 124 | 0.200 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2026 | 269 | 0.190 |
Why?
|
| Vaccines, Combined | 1 | 2022 | 40 | 0.190 |
Why?
|
| Borrelia burgdorferi Group | 1 | 2022 | 4 | 0.190 |
Why?
|
| Antiparasitic Agents | 1 | 2022 | 28 | 0.190 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 463 | 0.180 |
Why?
|
| Interleukin-4 | 1 | 2022 | 144 | 0.180 |
Why?
|
| Humans | 21 | 2026 | 131163 | 0.180 |
Why?
|
| Antibodies, Protozoan | 1 | 2022 | 102 | 0.180 |
Why?
|
| Viral Load | 2 | 2021 | 416 | 0.180 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2012 | 79 | 0.180 |
Why?
|
| Borrelia | 1 | 2022 | 84 | 0.170 |
Why?
|
| Fermentation | 2 | 2020 | 67 | 0.170 |
Why?
|
| Aluminum Hydroxide | 1 | 2020 | 43 | 0.160 |
Why?
|
| Leishmania | 1 | 2020 | 34 | 0.160 |
Why?
|
| Adsorption | 4 | 2014 | 33 | 0.160 |
Why?
|
| Ticks | 1 | 2020 | 34 | 0.150 |
Why?
|
| Pepsin A | 1 | 2019 | 11 | 0.150 |
Why?
|
| Aspartic Acid Proteases | 1 | 2019 | 9 | 0.150 |
Why?
|
| Protein Subunits | 1 | 2020 | 157 | 0.150 |
Why?
|
| Cytokines | 2 | 2022 | 1339 | 0.150 |
Why?
|
| Protein Structure, Tertiary | 1 | 2021 | 716 | 0.150 |
Why?
|
| Amino Acid Sequence | 2 | 2021 | 2395 | 0.150 |
Why?
|
| Ultraviolet Rays | 1 | 2019 | 192 | 0.140 |
Why?
|
| Proteins | 2 | 2014 | 1006 | 0.130 |
Why?
|
| Industrial Microbiology | 1 | 2017 | 8 | 0.130 |
Why?
|
| Antigens, Protozoan | 1 | 2017 | 77 | 0.130 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 325 | 0.120 |
Why?
|
| Stochastic Processes | 1 | 2014 | 35 | 0.100 |
Why?
|
| Sepharose | 1 | 2013 | 9 | 0.100 |
Why?
|
| Spermine | 1 | 2013 | 7 | 0.100 |
Why?
|
| Levivirus | 1 | 2013 | 3 | 0.100 |
Why?
|
| Glycosylation | 1 | 2013 | 127 | 0.100 |
Why?
|
| Encephalitis Virus, Japanese | 1 | 2013 | 24 | 0.100 |
Why?
|
| Administration, Intranasal | 2 | 2024 | 130 | 0.100 |
Why?
|
| Aptamers, Nucleotide | 1 | 2013 | 37 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 325 | 0.080 |
Why?
|
| Salmon | 1 | 2010 | 5 | 0.080 |
Why?
|
| Osmolar Concentration | 1 | 2010 | 148 | 0.080 |
Why?
|
| Sodium Chloride | 1 | 2010 | 89 | 0.080 |
Why?
|
| Nanoparticles | 1 | 2013 | 310 | 0.080 |
Why?
|
| Female | 7 | 2026 | 70963 | 0.080 |
Why?
|
| Antibodies | 2 | 2022 | 322 | 0.080 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 235 | 0.080 |
Why?
|
| Peptides | 1 | 2012 | 708 | 0.070 |
Why?
|
| Protein Stability | 2 | 2020 | 165 | 0.070 |
Why?
|
| Binding Sites | 2 | 2022 | 1133 | 0.070 |
Why?
|
| Models, Molecular | 2 | 2025 | 1064 | 0.060 |
Why?
|
| South Africa | 1 | 2026 | 98 | 0.060 |
Why?
|
| Freeze Drying | 1 | 2024 | 13 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2024 | 185 | 0.050 |
Why?
|
| Lactalbumin | 2 | 2014 | 12 | 0.050 |
Why?
|
| Crystallography, X-Ray | 1 | 2025 | 364 | 0.050 |
Why?
|
| Protein Binding | 2 | 2021 | 1652 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 158 | 0.050 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2024 | 116 | 0.050 |
Why?
|
| Antigens, Bacterial | 1 | 2025 | 319 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2025 | 406 | 0.050 |
Why?
|
| Technology | 1 | 2023 | 68 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2026 | 1410 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2026 | 1287 | 0.050 |
Why?
|
| Cattle | 2 | 2013 | 501 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 120 | 0.040 |
Why?
|
| Survival Rate | 1 | 2026 | 2114 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 193 | 0.040 |
Why?
|
| Molecular Weight | 1 | 2020 | 276 | 0.040 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2020 | 50 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2020 | 95 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 2020 | 58 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2021 | 504 | 0.040 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2019 | 40 | 0.040 |
Why?
|
| Health Resources | 1 | 2021 | 131 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2025 | 981 | 0.040 |
Why?
|
| Protein Folding | 1 | 2019 | 214 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 500 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 786 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2024 | 991 | 0.030 |
Why?
|
| Freezing | 1 | 2017 | 27 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2019 | 732 | 0.030 |
Why?
|
| Temperature | 1 | 2017 | 291 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2020 | 892 | 0.030 |
Why?
|
| Cell Line | 1 | 2021 | 2552 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1129 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2904 | 0.030 |
Why?
|
| RNA, Fungal | 1 | 2013 | 13 | 0.030 |
Why?
|
| Horseradish Peroxidase | 1 | 2013 | 14 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2014 | 74 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 1535 | 0.020 |
Why?
|
| Muramidase | 1 | 2013 | 37 | 0.020 |
Why?
|
| Serum Albumin, Bovine | 1 | 2013 | 37 | 0.020 |
Why?
|
| Chickens | 1 | 2013 | 267 | 0.020 |
Why?
|
| Ligands | 1 | 2013 | 481 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1722 | 0.020 |
Why?
|
| Kinetics | 1 | 2014 | 1088 | 0.020 |
Why?
|
| Surface Properties | 1 | 2011 | 81 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 366 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2026 | 12936 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 3464 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2026 | 17753 | 0.020 |
Why?
|
| Middle Aged | 1 | 2026 | 28601 | 0.010 |
Why?
|
| Adult | 1 | 2026 | 31282 | 0.010 |
Why?
|
| Male | 1 | 2021 | 64957 | 0.010 |
Why?
|